- Home
- XXI vs SYRE Comparison
XXI vs SYRE Comparison
Compare XXI & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$40.40
Company Overview
Basic Information| Metric | XXI | SYRE |
|---|---|---|
| Founded | 2025 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.1B | 2.6B |
| IPO Year | N/A | 2015 |
Fundamental Metrics
Financial Performance| Metric | XXI | SYRE |
|---|---|---|
| Price | $6.70 | $40.40 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $55.57 |
| AVG Volume (30 Days) | ★ 784.0K | 676.8K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.61 | $10.91 |
| 52 Week High | $11.49 | $45.76 |
Technical Indicators
Market Signals| Indicator | XXI | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 48.57 | 56.18 |
| Support Level | $5.79 | $15.01 |
| Resistance Level | $9.97 | $45.76 |
| Average True Range (ATR) | 0.36 | 2.03 |
| MACD | 0.18 | -0.36 |
| Stochastic Oscillator | 71.24 | 29.73 |
Price Performance
Historical Comparison XXI
SYRE
About XXI Twenty One Capital Inc. Class A Common Stock
Twenty One Capital Inc has no operation history.
About SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.